Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co. Ltd. announced that they have entered into distribution and supply agreements to provide INBRIJA®? in China.

INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a carbidopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million upon regulatory approval, up to $132.5 million in sales milestones, and a fixed fee for each carton of INBRIJA supplied to Chance. By 2030, it is estimated that China will have approximately 5 million people with Parkinson's diseasedue to its aging population1.

Chance plans to seek regulatory authorization as quickly as possible. Chance Pharmaceuticals is focused on developing and delivering novel inhalation therapies. Its Founder and CEO, Donghao Chen, Ph.D., received post-doctoral training in the laboratory of Dr. Bob Langer at M.I.T., which invented the ARCUS®?

inhalation technology used to make INBRIJA. He also worked at Advanced Inhalation Research (AIR) and Alkermes, where he was the CMC lead for an inhaled insulin therapy, also based on the ARCUS platform.